BullishWhales · Analysts · Analyst Profile
Analyst rating accuracy & track record
Chris Schott does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 TEVATeva Pharma Industries Ltd ADR | Buy | $23.00 | May 2025 | +92.3% | Hit |
 AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock | Buy | $12.00 | Feb 2025 | +64.6% | Hit |
 OGNOrganon & Co | Sell | $20.00 | Sep 2024 | +36.4% | Hit |
 PRGOPerrigo Company PLC | Buy | $41.00 | Feb 2024 | −7.7% | Miss |
 RPRXRoyalty Pharma Plc | Buy | $42.00 | Feb 2024 | +4.6% | Miss |
| PRGOPerrigo Company PLC | Buy | $48.00 | Aug 2023 | −37.3% | Miss |
| RPRXRoyalty Pharma Plc | Buy | $52.00 | Oct 2022 | −37.3% | Miss |
 KALAKala Pharmaceuticals Inc | Buy | $22.00 | Nov 2018 | −51.9% | Miss |
Go to
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.